Viewing Study NCT06058793


Ignite Creation Date: 2025-12-25 @ 1:22 AM
Ignite Modification Date: 2026-01-19 @ 11:41 AM
Study NCT ID: NCT06058793
Status: COMPLETED
Last Update Posted: 2025-12-19
First Post: 2023-09-22
Is Gene Therapy: True
Has Adverse Events: False

Brief Title: Brightline-4: A Study to Test How Well Brigimadlin is Tolerated by People With a Type of Cancer Called Dedifferentiated Liposarcoma
Sponsor: Boehringer Ingelheim
Organization:

Organization Data

Organization:
Class: INDUSTRY
Study ID: 1403-0019
Study Type: None
Study Domain: None
Study Link: None
Lead Sponsor:
Lead Sponsor Class: INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type: SPONSOR
Responsible Party Affiliation:
Old Name: None
Old Organization: None

Collaborators